Innovent Biologics Files for Hong Kong IPO
Chinese biotech firm, Innovent Biologics, backed by Singapore's Temasek Holdings, has filed for an initial public offering in Hong Kong, according to Caixin news agency.
The Suzhou-based company did not specify the size and pricing of the offering in its prospectus.
(Source: Innovent's Prospectus)
According to a Frost and Sullivan report commissioned by the company, biologic drugs are currently the top-selling pharmaceutical products in the world.